ActiGraph

Last month, we held our 3rd ActiGraph Digital Data Summit, bringing together clinical researchers who are passionate about advancing the use digital health to improve clinical research. ?? It was exciting to see the work presented and the conversations it inspired take a clear step forward. ?? In this issue, we give some examples of this exciting progress using digital health technology to provide unique clinical insights in areas such as immunology and immunotherapy. We also share more details on how ActiGraph's expanded technology and scientific products support our customers more broadly through patient-focused digital data. #DigitalHealthTechnology #Immunology #AutoimmuneDisease #Immunotherapy #Oncology #CancerCare #ADDS2025 #NHANES #HIMSS25 #MDA2025

A single rare disease affects a small percent of the population, but collectively there are over 6,000 different rare diseases. These rare diseases affect over 300 million people worldwide, which equals the population of the world's 3rd largest country. ???Today, we'd like to contribute to raising awareness of rare diseases and the impact they have on patients' lives, and thank everyone who is working towards helping to advance treatments for these conditions. Learn more about the impact of rare diseases at ??https://hubs.la/Q038RrBg0 Many of the FDA's Patient-Focused Drug Development Meeting Reports summarize the views of patients with rare diseases, including what symptoms have the most significant impact on their lives and their perspectives on treatments. Understanding what matters to patients with rare diseases helps us develop more effective and meaningful treatments. ?? In our Patient-Focused Digital Measures Library, we've summarized the most significant symptoms reported by patients and how digital health technologies can measure these meaningful aspects of health to help evaluate new treatments for rare diseases such as amyotrophic lateral sclerosis (ALS), myotonic dystrophy (DM), spinal muscular atrophy (SMA), Kennedy's disease, narcolepsy, idiopathic pulmonary fibrosis, and inclusion body myositis: https://hubs.la/Q038Rs1l0 We hope to continue bringing awareness to the impact of rare diseases and help to advance therapies for patients with these conditions. #RareDiseaseDay2025

??♂? Physical activity is one of the key factors in sustaining weight loss, preserving muscle mass, and achieving long-term health benefits. Read the recent article in pharmaphorum by Christine Cong Guo to learn more about how adding objective measures of physical activity to clinical trials can help us better understand the influence of medication and lifestyle factors on weight loss and muscle mass, providing more robust data on treatment effects. ?? ??https://hubs.ly/Q038sMp40 #Obesity #DrugDevelopment #GLP1 #PhysicalActivity #DigitalMeasures #WeightLoss #MuscleMass #HealthBenefits

Will you be at the 2025 HIMSS Global Health Conference and Exhibition in Las Vegas next week? Join us for an engaging panel discussion, Revolutionizing Drug Development Through Strategic and Evidence-Driven Digital Health Innovations, featuring panelists - Jaydev Thakkar, #ActiGraph Kristen Sowalsky, PhD, DC, Clario Sakshi S., Critical Path Institute (C-Path) Fatta B. Nahab MD, FAAN, FANA, Neuron23 ?? March 6 | 9:45AM ?? Venetian | Level 3 | Murano 3204 #HIMSS25 #DigitalHealth #DrugDevelopment

Did you know? The number of sensor-based digital health technologies (DHTs) in industry-sponsored interventional trials has increased 10-fold over the last 5 years! This observation from the Library of Digital Endpoints (organized by Digital Medicine Society (DiMe)) speaks to the value that DHTs bring to clinical trials. If you’re interested in using DHTs in your study, the V3+ framework is an excellent resource. Recently updated to also include usability validation, this new publication describes a pragmatic approach to ensuring that sensor-based DHTs can be used optimally at scale by diverse users. Read the full paper here > https://hubs.la/Q0380RQ00 #DigitalHealthTechnology #DigitalEndpoints #ClinicalTrials #V3+Framework #UsabilityValidation

#ActiGraph Senior Data Scientist Michael Pettinati dives into the promise and the challenges of immunotherapy treatments, and how digital health technology can help us tackle a major challenge in immunotherapy – cytokine release syndrome. Read the full article here ?? https://hubs.la/Q037BNBw0 ? He shares lessons learned in specific studies, including critical insights into operational and technical considerations for collecting high-quality data and how to better standardize data collection. *?? These lessons are important because they help us advance the use of DHTs to provide a deeper understanding of immunotherapies, more uniform care, and enable algorithm development that can increase access to these treatments for patients with cancer and immunological diseases. #CytokineReleaseSyndrome #CRS #Immunotherapy #CancerCare #Oncology #Immunology #DigitalHealthTechnology #DataScience

#ActiGraph is proud to participate in the De-Risking Cytokine Release Syndrome project with DATAcc by Digital Medicine Society (DiMe).? ? ?? Cytokine Release Syndrome (CRS) is a severe and potentially life-threatening side effect of immunotherapy, a treatment that uses a person's immune system to fight cancer. Digital health technologies can help detect CRS more quickly and mitigate the risk it poses to patients' health.?? ? ?? The resources developed by project partners are now available! This collection is an important step to advance the application of digital tools that could help detect CRS more effectively, with the goal of improving patient safety and outcomes.? See more details below, and access the new resources here ?? https://lnkd.in/eKFbSXvd #CytokineReleaseSyndrome #CRS #Immunotherapy #CancerCare #Oncology #DigitalHealthTechnologies

? Last Call to Register! ? Join us during our Digital Health Monthly webinar on February 20 at 12 PM ET to explore how ActiGraph’s acquisition of Biofourmis Connect is modernizing clinical research with a connected digital health ecosystem. Learn more in the video below before joining us for more details during the webinar about: ?? the motivation behind the acquisition ?? the details of our integration ?? how your clinical development team can access AI-driven analytics from high-quality, rich digital data to reshape patient-centric trial designs Don’t miss your opportunity to gain industry insights into cutting-edge technology and ask questions about the new platform – Register today! ??https://hubs.la/Q037b-ln0

We would like to thank all of the speakers, sponsors, poster presenters, and attendees for making the 3rd ActiGraph Digital Data Summit a successful event! It was an honor to host digital health leaders from across the world, who came together for multiple productive days of sharing data and lessons learned. Discussions about where specifically we go from here and how we get there were inspired by - ?? Presentations describing studies with many participants in healthy populations and in people with diseases like #ALS or #cancer that showed high compliance rates with wearable digital health technology ?? Data from studies analyzing which specific digital measures are meaningful and insights on collecting that data in specific disease states such as #NMD and #PAH ?? Guidance from a range of perspectives on engaging with regulators when incorporating DHTs into clinical trials ?? Using data from large-scale population studies and novel, AI-driven analysis techniques to refine and advance algorithms used to derive digital measures We believe these conversations and ensuing collaborations are needed to help drive digital innovation in clinical research forward, and are grateful to spend time with this passionate community. We look forward to sharing more takeaways from the conference in the coming weeks! #ADDS2025 #DigitalHealthTechnology #Wearables #DigitalMeasures #DigitalEndpoints #ClinicalResearch #ClinicalTrials #Collaboration

?? NEW resources alert! Today, during a public launch event, DATAcc by DiMe unveiled new resources to support #CytokineReleaseSyndrome (CRS) risk prediction and management. These resources support developers in building reliable CRS de-risking products that improve patient safety and outcomes and reshape the future of #cancercare. ?? Use these resources to support the development of CRS de-risking products by implementing uniform CRS measures collection and a strategic development plan: ?? Building CRS De-risking Products: A Practical Guide for Developers ?? Common Digital Clinical Measures to De-risk CRS ?? CRS Innovation Roadmap These resources empower developers, clinicians, and researchers to develop advanced, trustworthy CRS de-risking products. By reducing the need for inpatient care and enabling outpatient treatments, we can lighten the burden on patients, caregivers, and healthcare systems. ?? Access these resources now and join us in transforming cancer care: https://bit.ly/4hGxEGH Let’s make immunotherapies safer, accessible, and equitable for every patient who needs them. ?? Association of Cancer Care Centers ActiGraph Analog Devices Atrium Health Best Buy Health Biofourmis Blue Spark Technologies Bristol Myers Squibb Canopy Doccla Foundation for the National Institutes of Health Friends of Cancer Research Genentech IEEE Johnson & Johnson Innovative Medicine The Leukemia & Lymphoma Society Mika Orion Pharma Pfizer Takeda Verily National Cancer Institute (NCI)